Initiation of aripiprazole once-monthly in patients with schizophrenia

Current Medical Research and Opinion

Volumn 31, Issue 3, 2015, Pages 583-592

  Raoufinia, Arash ^a   Baker, Ross A ^a   Eramo, Anna ^b   Nylander, Anna Greta ^c   Landsberg, Wally ^d   Kostic, Dusan ^a   Larsen, Frank ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b LUNDBECK RESEARCH USA   (United States)

^c H LUNDBECK A S   (Denmark)

^d Otsuka Pharmaceutical Europe Limited   (United Kingdom)

Author keywords

Antipsychotic; Aripiprazole once monthly; Dosing information; Long acting injectable; Schizophrenia; Switching; Treatment initiation

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; DELAYED RELEASE FORMULATION; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AGITATION; AKATHISIA; ANXIETY; AREA UNDER THE CURVE; CLINICAL STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INJECTION SITE PAIN; INSOMNIA; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OPTIMAL DRUG DOSE; POST HOC ANALYSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SKIN ALLERGY; SOMNOLENCE; WEIGHT GAIN; ADULT; BLOOD; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; INJECTION; MALE; MEDICAL RESEARCH; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84924614745     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1006356     Document Type: Review

References (27)

1. DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008;34:312-21
2. Modestin J, Huber A, Satirli E, et al. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry 2003;160:2202-8
3. van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45
4. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res 2013;148:117-21
5. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014;152:408-14
6. Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20
7. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
8. Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
9. Abilify Maintena US (aripiprazole). Full Prescribing Information, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan. Available at: http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf. Accessed January 21, 2015
10. Abilify Maintena EU (aripiprazole). Full Prescribing Information, Otsuka Pharmaceutical Europe Ltd, Wexham, UK. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000471/WC500020170.pdf. [Last accessed January 21, 2015]
11. Abilify Maintena CAN (aripiprazole). Full Prescribing Information, Otsuka Canada Pharmaceutical Inc., Saint-Laurent, QC, Canada. Available at: webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00020719. [Last accessed January 21, 2015]
12. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9
13. Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
14. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135-44
15. Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013;150:281-8
16. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87
17. Kirschbaum KM, Muller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008;9:212-18
18. Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin 2013;29:1241-51
19. Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75:1254-60
20. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
21. Kane JM, Zhao C, Johnson B, et al. Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2014; Epub Nov 10. DOI: 10.3111/13696998.2014.979936
22. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25:S12-21
23. Correll CU, Agarwal V, Kane JM. Gradual and Overlapping Antipsychotic Switch Strategies are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-Analysis of Different Switch Strategies. Waikoloa, HI, USA: American College of Neuropsychopharmacology, 4-8 December 2011
24. Correll CU. Real-life switching strategies with second-generation antipsych-otics. J Clin Psychiatry 2006;67:160-1
25. Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23:1733-44
26. Baker R, Eramo A, Nylander A-G, et al. The effect of previous dose of oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: results from post-hoc analyses from two double-blind, randomized, controlled trials. 4th Schizophrenia International Research Society Conference, Florence, Italy, 5-9 April 2014
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76